



Commercial/Healthcare Exchange PA Criteria
Effective: March 2008

Prior Authorization: Remodulin

Products Affected: Remodulin (treprostinil) injection

Medication Description: Treprostinil is a direct vasodilator of both pulmonary and systemic arterial vascular beds; also inhibits platelet aggregation.

Covered Uses:

1. Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.
2. Treatment of pulmonary arterial hypertension (PAH) in patients requiring transition from epoprostenol.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. New York Heart Association classification
3. World Health Organization (WHO) functional class
4. Previous therapies tried/failed

Age Restrictions: N/A

Prescriber Restrictions: Prescribed by, or in consultation with, a pulmonologist or a cardiologist

Coverage Duration: 12 months

Other Criteria:

Pulmonary arterial hypertension (PAH)

1. Patient has Who Group 1 PAH;**AND**
2. Patient exhibits New York Heart Association Class II to IV symptoms; **AND**
3. Patient has had an intolerance to, or treatment failure of a calcium channel blocker after favorable response to acute vasoreactivity testing OR failure to have a pulmonary vasodilator response to an acute challenge of a short acting vasodilator; **AND**
4. Patient has tried and failed, or has an intolerance to, contraindication*, or treatment failure to Tracleer (bosentan).

Pulmonary arterial hypertension in patients transitioning from epoprostenol

1. Patient has Who Group 1 PAH;**AND**
2. Patient exhibits New York Heart Association Class II to IV symptoms

Last Res.September 2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

References:

1. Remodulin (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; September 2020.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	Update	<p>Adopted EH template</p> <p>Removed from PAH CCI policy, previous revision history: 3/08, 6/10, 5/16, 11/12, 11/16, 11/17, 9/18, 11/18, 9/18, 10/18, 5/19</p> <p>Removed Other Criteria: Patient exhibits New York heart association (NYHA) Class II or IV symptoms</p> <p>Added indication: Pulmonary arterial hypertension in patients transitioning from epoprostenol</p>	All	9/22/2020